On December 2, 2023, BioCardia shared an exciting update following their consultation with Japan's PMDA regarding the groundbreaking CardiAMP Autologous ...
Unique Text: BioCardia, a leading biotechnology company, has made an exciting announcement regarding its registered direct offering. The company plans ...
BioCardia Inc's (NASDAQ: BCDA) stock has experienced a remarkable surge of 225.70% following the FDA's recent approval of the Phase ...
On November 15, 2023, BioCardia achieved a major breakthrough as it obtained FDA authorization for its groundbreaking CardiAMP Heart Failure ...
On November 8, 2023, BioCardia (NASDAQ:BCDA) is scheduled to unveil its quarterly earnings report. Market analysts have projected an earnings ...
On November 8, 2023, BioCardia (NASDAQ:BCDA) is scheduled to unveil its latest quarterly earnings report, marking an important milestone for ...
BioCardia, Inc., a pioneering regenerative medicine company specializing in cardiovascular disease treatments, recently filed for a mixed shelf offering of ...
On October 11, 2023, Joseph Pantginis, an analyst at HC Wainwright & Co., expressed his continued confidence in BioCardia (NASDAQ: ...
BioCardia, a leading developer in the field of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has recently accomplished ...
On September 5, 2023, BioCardia, a cutting-edge company specializing in regenerative medicine, unveiled the latest findings from the phase III ...